MLYS Share Price Performance
US$29.85
14.12 (89.76%)
41.3% undervalued intrinsic discount
US$50.88
Fair Value
Price US$29.85
AnalystConsensusTarget US$50.88
AnalystHighTarget US$56.00
AnalystLowTarget US$33.82
Fair ValueUS$50.88
Share Pricen/a
Mineralys Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
MLYS Community Narratives
AN
Fair Value
·Fair Value US$50.88 41.3% undervalued intrinsic discount
Hypertension And Cardiorenal Catalysts Will Reshape Long Term Prospects For This Biotech
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value US$56 46.7% undervalued intrinsic discount
Hypertension PDUFA Decision And Large Target Population Will Support Strong Long Term Opportunity
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$33.82 11.7% undervalued intrinsic discount
Regulatory And Competitive Pressures Will Challenge Hypertension Launch Yet Longer Term Potential Remains
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regulatory And Competitive Pressures Will Challenge Hypertension Launch Yet Longer Term Potential Remains
Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor for adults with uncontrolled or resistant hypertension and related comorbidities. What are the underlying business or industry changes driving this perspective?Read more
AN
US$33.82
11.7% undervalued intrinsic discount
Fair Value
Profit Margin
14.76%
Future PE
193.69x
Price in 2029
US$0
Hypertension PDUFA Decision And Large Target Population Will Support Strong Long Term Opportunity
Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor for patients with uncontrolled and resistant hypertension. What are the underlying business or industry changes driving this perspective?Read more
AN
US$56
46.7% undervalued intrinsic discount
Fair Value
Profit Margin
12.51%
Future PE
143x
Price in 2029
US$0
Hypertension And Cardiorenal Catalysts Will Reshape Long Term Prospects For This Biotech
Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor, for patients with uncontrolled and resistant hypertension and related cardiorenal conditions. What are the underlying business or industry changes driving this perspective?Read more
AN
US$50.88
41.3% undervalued intrinsic discount
Fair Value
Profit Margin
10.89%
Future PE
257.65x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Regulatory And Competitive Pressures Will Challenge Hypertension Launch Yet Longer Term Potential Remains
Fair Value: US$33.82 11.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Hypertension PDUFA Decision And Large Target Population Will Support Strong Long Term Opportunity
Fair Value: US$56 46.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Hypertension And Cardiorenal Catalysts Will Reshape Long Term Prospects For This Biotech
Fair Value: US$50.88 41.3% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Mineralys Therapeutics, Inc. Key Details
About MLYS
- Founded
- 2019
- Employees
- 76
- CEO
- WebsiteView website
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
